Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Christina Arce"'
Autor:
Stephen Chia, Eva M Ciruelos, Hope S Rugo, Florence Lerebours, Manuel Ruiz-Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Nicholas Turner, Ennan Gu, Christina Arce, Murat Akdere, Dejan Juric
Publikováno v:
Cancer Research. 82:P1-18
Introduction: PIK3CA (encoding phosphatidylinositol 3-kinase alpha [PI3Kα]) is a driver oncogene mutated (mut) in ~40% of HR+, HER2- ABCs, leading to endocrine therapy (ET) resistance and poor prognosis. Alpelisib (ALP) is the first oral α-selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bac0d3b6315a3676442e2df3b15c7e52
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-08
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-08
Autor:
Yu-Ming Shen, Dejan Juric, Murat Akdere, Aleix Prat, Hope S. Rugo, Stephen Chia, Christina Arce, Florence Lerebours, Nicholas C. Turner, Eva Ciruelos, Pamela Drullinsky, Rafael Villanueva Vazquez
Publikováno v:
Cancer Research. 81:PD2-07
Introduction: Mutations in PIK3CA, which encodes the α-isoform of phosphatidylinositol 3-kinase (PI3Kα), occur in ~40% of patients (pts) with HR+, HER2- ABC and can contribute to endocrine resistance. Alpelisib (ALP), a PI3Kα-selective inhibitor a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0177127221592a9e20d0906b8b224c4d
https://doi.org/10.1158/1538-7445.sabcs20-pd2-07
https://doi.org/10.1158/1538-7445.sabcs20-pd2-07
Autor:
Stuart J. Turner, Stephen Chia, Nicholas C. Turner, Wei-Chun Hsu, Yeon Hee Park, Patrick Neven, Florence Lerebours, Pamela Drullinsky, Christina Arce, Manuel Ruiz-Borrego, Yu-Ming Shen, Eva Ciruelos, Juan Pablo Zarate, Hope S. Rugo, Nickolas Sophos, Dejan Juric, Aleix Prat, Thomas Bachelot, Hemanth Kanakamedala
Publikováno v:
The Lancet Oncology. 22:489-498
Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c841d63ed9181f985f1497efcc691d43
https://doi.org/10.1016/s1470-2045(21)00034-6
https://doi.org/10.1016/s1470-2045(21)00034-6
Autor:
Ennan Gu, Hope S. Rugo, Aleix Prat, Eva Ciruelos, Murat Akdere, Stephen Chia, Christina Arce, Pamela Drullinsky, Florence Lerebours, Manuel Ruiz-Borrego, Nicholas C. Turner, Thomas Bachelot, Dejan Juric
Publikováno v:
Journal of Clinical Oncology. 39:1060-1060
1060 Background: Mutations in PIK3CA (encoding PI3Kα) are present in ̃40% of HR+, HER2– ABC tumors and are associated with relative endocrine resistance and poor prognosis. ALP inhibits and degrades PI3Kα. Primary analyses of Cohorts A and B fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8196b06e0f7a577c5f5c32ec974c728f
https://doi.org/10.1200/jco.2021.39.15_suppl.1060
https://doi.org/10.1200/jco.2021.39.15_suppl.1060
Autor:
Thomas Bachelot, Manuel Ruiz Borrego, Yu-Ming Shen, Juan Pablo Zarate, Florence Lerebours, Aleix Prat, Christina Arce, Nicholas C. Turner, Eva Ciruelos, Stephen Chia, Nickolas Sophos, Hope S. Rugo, Pamela Drullinsky, Dejan Juric, Yeon Hee Park, Patrick Neven
Publikováno v:
Journal of Clinical Oncology. 38:1006-1006
1006 Background: PIK3CA mutations (mut) occur in ~40% of pts with HR+, HER2– ABC and are associated with poor prognosis and resistance to treatment (tx). ALP, a PI3Kα inhibitor, plus FUL demonstrated efficacy in the phase 3 SOLAR-1 trial of HR+, H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86048837117076a0a6a2f4f9b2d523c6
https://doi.org/10.1200/jco.2020.38.15_suppl.1006
https://doi.org/10.1200/jco.2020.38.15_suppl.1006
Autor:
Marc Debled, Carla I. Falkson, Christina Arce, Antonia Ridolfi, Felipe Melo Cruz, Vichien Srimuninnimit, Joon Jeong, Melanie Royce, Chinjune Lin, Cristian Villanueva, Sergio J. Azevedo, Roberto Hegg, Thomas Bachelot, Fatima Cardoso, Mustafa Ozguroglu, William J. Gradishar, Tatsuya Toyama
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Importance Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. Objective To investigate the combination of everol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8e14e194faccf0ce78a9da0b63bfde
https://pubmed.ncbi.nlm.nih.gov/29566104
https://pubmed.ncbi.nlm.nih.gov/29566104
Autor:
Carla I. Falkson, William J. Gradishar, Chinjune Lin, Vichien Srimuninnimit, F. Melo Cruz, Fatima Cardoso, Mustafa Ozguroglu, Roberto Hegg, Antonia Ridolfi, Cristian Villanueva, J. Jeong, Christina Arce, Thomas Bachelot, Melanie Royce, Sergio J Azevedo
Publikováno v:
Annals of Oncology. 28:v77-v78
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be8b0f8103e3fb02e5c7d68f894cfb6c
https://doi.org/10.1093/annonc/mdx365.007
https://doi.org/10.1093/annonc/mdx365.007
Autor:
Woo Chul Noh, V. Srimuninnimit, Joon Jeong, Chinjune Lin, V. Sriuranpong, Fatima Cardoso, Christina Arce, Hirotaka Iwase, Antonia Ridolfi, Tatsuya Toyama, Masato Takahashi, K. Tsugawa, Melanie Royce
Publikováno v:
Annals of Oncology. 28:x26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::851995ae29e49347161d8f05098ad423
https://doi.org/10.1093/annonc/mdx654
https://doi.org/10.1093/annonc/mdx654
Autor:
Felipe Melo Cruz, Chinjune Lin, Antonia Ridolfi, Marc Debled, William J. Gradishar, Thomas Bachelot, Vichien Srimuninnimit, Joon Jeong, Cristian Villanueva, Fatima Cardoso, Mustafa Ozguroglu, Roberto Hegg, Tatsuya Toyama, Christina Arce, Melanie Royce, Sergio J Azevedo, Carla I. Falkson
Publikováno v:
Journal of Clinical Oncology. 35:1010-1010
1010 Background: Initial first-line (1L) data from the phase 2 BOLERO-4 (NCT01698918) study of EVE + letrozole (LET) in postmenopausal patients (pts) with ER+, HER2− metastatic BC (MBC) or locally advanced BC (LABC) have been previously reported. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08a7fb9981fc8b425391e7ee0443d3fe
https://doi.org/10.1200/jco.2017.35.15_suppl.1010
https://doi.org/10.1200/jco.2017.35.15_suppl.1010
Autor:
Rudy Onia, Ingrid Eshun-Wilson, Christina Arce, Christopher Ellis, Valentin Parvu, David Hassman, Kenneth Kassler-Taub
Publikováno v:
Current Medical Research & Opinion; Jul2011, Vol. 27 Issue 7, p1339-1346, 8p